FDA Offers Technical Specs and Considerations for ANDAs

The FDA issued guidance Wednesday recommending technical specifications and general considerations on how certain comparative clinical endpoint bioequivalence study data and skin adhesion and irritation/sensitization study data for ANDAs should be submitted using FDA-supported data standards.
Source: Drug Industry Daily

No announcement available or all announcement expired.